Department of Cardiovascular, Respiratory, Nephrological, Aenesthesiological and Geriatric Sciences "Sapienza", University of Rome, Rome, Italy.
St. David's Medical Center, Texas Cardiac Arrhythmia Institute, Austin, Texas, USA.
Pacing Clin Electrophysiol. 2022 Apr;45(4):519-531. doi: 10.1111/pace.14462. Epub 2022 Feb 21.
Catheter ablation of papillary muscle ventricular arrhythmias (PM-VAs) has been associated with unsatisfactory results. Features that may affect acute and long-term procedural outcomes are not well established.
To systematically review the available data in the literature assessing efficacy and safety of PM-VAs catheter ablation.
An online search of PubMed, Cochrane Registry, Web of Science, Scopus and EMBASE libraries (from inception to March 1, 2021) was performed, in addition to manual screening. Twenty-one observational noncontrolled case-series were considered eligible for the systematic review, including 536 patients.
Postero-medial PM harbored 60.8% of PM-VAs, while antero-lateral PM and right ventricular PMs 34.9% and 4.3% of cases, respectively. The mean acute success rate of the index ablation procedure was 88.1% (95% CI 82.8% to 91.9%, p < .001, I 0%). After a mean follow-up period of 15.5 ± 17.4 months, pooled long-term arrhythmia-free rate was 69.2%, while the pooled long-term success rate after multiple ablation procedure was 84.9%. Overall, procedure complications occurred in nine patients (1.7%) and no procedure-related deaths were reported. The use of intracardiac echocardiography (ICE) as well as contact force sensing (CFS) and irrigated catheters during ablation was associated with higher rates of arrhythmia-freedom at long-term follow-up.
Catheter ablation is an effective and safe strategy for PM-VAs, with an acute success rate of 88.1%, a long-term success rate of 69.2%, with a relatively low procedural complication rate. The use of ICE, irrigated catheters and catheters with CFS capability was associated with higher rates of arrhythmia-freedom at long-term follow-up.
乳头肌室性心律失常(PM-VAs)的导管消融与不满意的结果相关。影响急性和长期手术结果的特征尚不清楚。
系统地回顾评估乳头肌室性心律失常导管消融的有效性和安全性的现有文献数据。
对 PubMed、Cochrane 注册中心、Web of Science、Scopus 和 EMBASE 数据库(从建库至 2021 年 3 月 1 日)进行在线检索,同时进行手动筛选。共纳入 21 项观察性非对照病例系列研究,共计 536 例患者。
后内侧乳头肌为 60.8%的 PM-VAs 起源部位,前外侧乳头肌和右心室乳头肌分别为 34.9%和 4.3%。索引消融术的平均急性成功率为 88.1%(95%CI:82.8%至 91.9%,p<0.001,I²=0%)。平均随访 15.5±17.4 个月后,汇总的长期无心律失常率为 69.2%,多次消融后汇总的长期成功率为 84.9%。总体而言,9 例(1.7%)患者发生手术并发症,无手术相关死亡报告。消融过程中使用心腔内超声(ICE)、接触力感知(CFS)和灌流导管与长期随访时的无心律失常率较高相关。
导管消融是治疗 PM-VAs 的一种有效且安全的策略,急性成功率为 88.1%,长期成功率为 69.2%,手术并发症发生率相对较低。使用 ICE、灌流导管和具有 CFS 功能的导管与长期随访时的无心律失常率较高相关。